While early‐stage NSCLC is generally treated via surgery, the appreciable number of patients is diagnosed at advanced stages leading to a poor prognosis.[33] Chemotherapy, particularly with cisplatin and taxanes (docetaxel or paclitaxel), is a main treatment for advanced cancers, but resistance to cisplatin and taxanes is becoming a major therapeutic challenge.[2] In the present study, we identified CypA as a key player in chemotherapy resistance. Here, PPIA is linked to non-small cell lung carcinoma.